Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Type 2 Diabetes (DPP4 and Combo) (Nov 2020)

Posted by Matt Breese on Nov 27, 2020

Find me on:

According to our recent payer coverage analysis for type 2 Diabetes (DPP4 and Combo) treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for type 2 Diabetes (DPP4 and Combo) treatments shows that under the pharmacy benefit, almost 40% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-Diabetes DPP4-4Q2020Data snapshot as of Q4 2020

Trends: In December 2019, Lexicon Pharmaceuticals, Inc. reported topline data from their Phase III SOTA-EMPA study for Zynquista (sotagliflozin) in type 2 diabetes, according to the company.  

To read the full Reality Check on Type 2 Diabetes (DPP4 and Combo) treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing